NASDAQ:PRTG Portage Biotech Q1 2024 Earnings Report $8.65 +1.63 (+23.22%) Closing price 03:59 PM EasternExtended Trading$8.49 -0.16 (-1.85%) As of 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings History Portage Biotech EPS ResultsActual EPS-$6.60Consensus EPS -$4.80Beat/MissMissed by -$1.80One Year Ago EPSN/APortage Biotech Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/APortage Biotech Announcement DetailsQuarterQ1 2024Date8/30/2023TimeQ1 2024 Earnings ReleaseConference Call DateWednesday, August 30, 2023Conference Call Time7:00AM ETUpcoming EarningsPortage Biotech's Q3 2025 earnings is scheduled for Tuesday, August 26, 2025Conference Call ResourcesPress Release (8-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K) Portage Biotech Earnings HeadlinesPortage Biotech Reports Results for Fiscal Year Ended March 31, 2025July 25, 2025 | globenewswire.comPortage Biotech Regains Nasdaq Compliance, Maintains Listing On Capital Market | NasdaqJune 27, 2025 | nasdaq.comINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.August 6 at 2:00 AM | Traders Agency (Ad)PRTG Portage Biotech Inc. - Seeking AlphaJune 26, 2025 | seekingalpha.comPortage Biotech Inc. (PRTG) Income Statement - Yahoo FinanceJune 26, 2025 | finance.yahoo.comPortage Biotech Regains Nasdaq ComplianceJune 25, 2025 | tipranks.comSee More Portage Biotech Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Portage Biotech? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Portage Biotech and other key companies, straight to your email. Email Address About Portage BiotechPortage Biotech (NASDAQ:PRTG), a clinical stage immune-oncology company, engages in the research and develops pharmaceutical and biotechnology products. Its product pipeline includes PORT-2 for treatment of refractory NSCLC, melanoma, and refractory melanoma that is in phase I and phase II clinical trials; PORT-3, for treatment of solid tumors, which is in phase I clinical trials; PORT-6, an A2AR inhibitor to treat A2A & A2B high solid tumors that is in phase Ia clinical trials; PORT-7, an A2AR inhibitor to treat A2A & A2B high solid tumors that is in phase Ib clinical trials; PORT-1, an intratumoral amphiphilic solutions for treatment of advanced soft tissue sarcoma, which is in phase 3 clinical trials; PORT-4, a nanolipogel co-formulations to treat of solid tumors that is in preclinical trials; and PORT-5, a VLP-STING to treat of solid tumors that is in preclinical trials. The company is based in Tortola, British Virgin Islands.View Portage Biotech ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Rivian Takes Earnings Hit—R2 Could Be the Stock's 2026 LifelinePalantir Stock Soars After Blowout Earnings ReportVertical Aerospace's New Deal and Earnings De-Risk ProductionAmazon's Earnings: What Comes Next and How to Play ItApple Stock: Big Earnings, Small Move—Time to Buy?Why Robinhood Just Added Upside Potential After a Q2 Earnings DipMicrosoft Blasts Past Earnings—What’s Next for MSFT? Upcoming Earnings Gilead Sciences (8/7/2025)Monster Beverage (8/7/2025)Constellation Energy (8/7/2025)Becton, Dickinson and Company (8/7/2025)Brookfield (8/7/2025)Canadian Natural Resources (8/7/2025)ConocoPhillips (8/7/2025)Diageo (8/7/2025)EOG Resources (8/7/2025)Flutter Entertainment (8/7/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
